ALXN2420

DRUG2 trials

Sponsors

Alexion Pharmaceuticals Inc., Alexion Pharmaceuticals, Inc.

Conditions

Acromegaly

Phase 2

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

TerminatedNCT07037420

Alexion Pharmaceuticals, Inc.Acromegaly

Start: 2025-10-28End: 2026-06-24Updated: 2026-08-07

A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose Range-finding, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALXN2420, a Growth Hormone Receptor Antagonist, Administered Subcutaneously in Combination with Somatostatin Analogs in Adult Participants with Acromegaly

RecruitingCTIS2025-521243-20-00

Alexion Pharmaceuticals Inc.Acromegaly

Start: 2025-10-23Target: 32Updated: 2026-01-08